Xponance Inc. Cuts Stake in LivaNova PLC (NASDAQ:LIVN)

Xponance Inc. cut its stake in LivaNova PLC (NASDAQ:LIVN) by 5.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,314 shares of the company’s stock after selling 433 shares during the quarter. Xponance Inc.’s holdings in LivaNova were worth $401,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. BNP Paribas Financial Markets lifted its position in shares of LivaNova by 88.6% in the first quarter. BNP Paribas Financial Markets now owns 42,121 shares of the company’s stock valued at $2,356,000 after acquiring an additional 19,783 shares in the last quarter. Great Lakes Advisors LLC purchased a new position in LivaNova in the 2nd quarter valued at $16,614,000. Quantbot Technologies LP acquired a new stake in LivaNova during the 1st quarter worth $994,000. Price T Rowe Associates Inc. MD grew its holdings in shares of LivaNova by 6.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 31,021 shares of the company’s stock worth $1,736,000 after buying an additional 1,980 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in shares of LivaNova by 963.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 31,565 shares of the company’s stock worth $1,633,000 after buying an additional 28,597 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

LIVN has been the topic of several recent research reports. Needham & Company LLC boosted their price target on shares of LivaNova from $72.00 to $75.00 and gave the company a “buy” rating in a research report on Wednesday, July 31st. Stifel Nicolaus increased their price objective on LivaNova from $70.00 to $72.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Baird R W upgraded LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 17th. Finally, Robert W. Baird upgraded LivaNova from a “neutral” rating to an “outperform” rating and increased their price target for the stock from $55.00 to $66.00 in a report on Tuesday, September 17th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, LivaNova presently has an average rating of “Buy” and a consensus target price of $70.80.

LivaNova Stock Performance

NASDAQ:LIVN opened at $52.54 on Tuesday. The company has a fifty day simple moving average of $48.67 and a two-hundred day simple moving average of $53.35. The company has a quick ratio of 2.94, a current ratio of 3.45 and a debt-to-equity ratio of 0.49. LivaNova PLC has a 52 week low of $42.75 and a 52 week high of $64.47. The company has a market cap of $2.85 billion, a price-to-earnings ratio of -87.57 and a beta of 1.00.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.81 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.15. The business had revenue of $318.60 million during the quarter, compared to the consensus estimate of $305.05 million. LivaNova had a negative net margin of 1.37% and a positive return on equity of 13.77%. As a group, equities analysts anticipate that LivaNova PLC will post 2.58 earnings per share for the current fiscal year.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.